Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

crizotinib

- PMLiVE

South African variant reduces antibody levels produced by Pifzer/BioNTech’s COVID-19 vaccine

Researchers noted it is 'unclear' what effect this reduction has on the vaccine's protection against the variant

- PMLiVE

Three strategies for managing loss of exclusivity successfully

Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.

Blue Latitude Health

- PMLiVE

US secures a further 100 million doses of Pfizer/BioNTech’s COVID-19 vaccine

US government will pay $1.95bn for additional 100 million doses

- PMLiVE

Pfizer’s basic instincts

Business model evolution can’t defy strategic gravity

- PMLiVE

Roche’s anti-inflammatory drug reduces deaths in hospitalised COVID-19 patients

Tocilizumab, marketed as Actemra/RoActemra, also reduced time spent in hospital in RECOVERY trial

- PMLiVE

EMA begins rolling review of CureVac’s COVID-19 vaccine

Investigational vaccine is currently being evaluated in a phase 2/3b clinical trial

- PMLiVE

AZ partners with IDT Biologika to bolster manufacturing for COVID-19 vaccine in EU

AZ is looking to accelerate vaccine output in Q2 2021

- PMLiVE

FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz

Post-marketing study shows increased risk of serious heart-related problems and cancer with Xeljanz

EU flag

EU orders another 300 million doses of Pfizer/BioNTech’s COVID-19 vaccine

Pfizer/BioNTech's has an existing agreement with the EU for an initial 300 million doses

Roche Basel Switzerland

Roche’s diagnostic business sales offer a bright spot in Q4

Company's pharmaceutical division sales slipped due to biosimilar competition

- PMLiVE

Pfizer aims for $15bn in 2021 COVID-19 vaccine sales

Current estimate is based on already agreed contracts

- PMLiVE

UK launches world-first COVID-19 study evaluating a mixed-vaccine regimen

Participants could receive AZ/Oxford University's vaccine for their first dose and Pfizer/BioNTech's vaccine for their second

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links